ストックスクリーナーアプリを入手
9.345
0.27%
0.025
アフターアワーズ：
9.44
0.095
+1.02%
前日終値:
$9.32
開ける：
$9.42
24時間の取引高:
316.33K
Relative Volume:
1.35
時価総額：
$127.51M
収益：
-
当期純損益:
$-104.29M
株価収益率:
-1.549
EPS:
-6.0329
ネットキャッシュフロー:
$-81.45M
1週間 パフォーマンス:
-12.01%
1か月 パフォーマンス:
-43.09%
6か月 パフォーマンス:
-29.20%
1年 パフォーマンス:
+4.03%
1日の値動き範囲:
$9.12
$9.50
1週間の範囲:
$9.0606
$11.28
52週間の値動き範囲:
$5.062
$17.43
Immunic Inc Stock (IMUX) Company Profile
Compare IMUX vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
9.345 | 127.51M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-17 | 開始されました | Stifel | Buy |
| 2026-04-15 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2026-03-24 | 開始されました | Guggenheim | Buy |
| 2025-11-07 | 開始されました | Roth Capital | Buy |
| 2025-09-29 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-25 | 開始されました | William Blair | Outperform |
| 2024-11-25 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-27 | 開始されました | B. Riley Securities | Buy |
| 2022-10-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2021-04-15 | 開始されました | Aegis Capital | Buy |
| 2021-03-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-02 | 開始されました | SVB Leerink | Outperform |
| 2020-08-26 | 開始されました | Piper Sandler | Overweight |
| 2020-08-07 | 再開されました | ROTH Capital | Buy |
| 2020-07-20 | 開始されました | BMO Capital Markets | Outperform |
| 2020-06-05 | 開始されました | Wedbush | Outperform |
| 2020-05-11 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-25 | 開始されました | ROTH Capital | Buy |
| 2019-07-11 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Immunic Inc (IMUX) 最新ニュース
Immunic, Inc. (IMUX) Options ChainYahoo Finance - ca.finance.yahoo.com
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic Inc (10V.HM) cash flow - Yahoo Finance UK
Immunic Inc (10V.HM) recent insider transactions - Yahoo Finance UK
10V.HM Interactive Stock Chart | Immunic Inc. R Stock - Yahoo Finance
Epstein-Barr Virus Market Set to Witness Growth with Emerging Immunotherapies and Vaccine Pipeline by 2036 – DelveInsight | Atara Biotherapeutics, Pierre Fabre Laboratories, Immunic Therapeutics - Barchart.com
H.C. Wainwright Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Director at Immunic (IMUX) gets options at $10.12 a share - stocktitan.net
New option grant tied to Immunic (IMUX) director - stocktitan.net
Roth MKM Maintains Immunic(IMUX.US) With Buy Rating, Raises Target Price to $29 - Moomoo
Immunic Appoints Chitrang Davé Chief Data and Digital Officer - CDO Magazine
Immunic announces resignation of director Duane Nash and board size reduction By Investing.com - Investing.com Australia
Immunic Director Dr. Duane Nash Resigns; Board Cut to Nine Members - minichart.com.sg
Form 8K Immunic Inc For: 11 September By Investing.com - Investing.com South Africa
Immunic announces resignation of director Duane Nash and board size reduction - Investing.com
Dr. Duane Nash resigns from Immunic board; board reduced to nine members - TradingView
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright reiterates Immunic stock rating on MS drug progress By Investing.com - Investing.com Nigeria
Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 BaselSlideshow (NASDAQ:IMUX) 2026-09-10 - Seeking Alpha
IMUX Reiterated by Wedbush -- Price Target Maintained at $45 - GuruFocus
Why Is Immunic (NASDAQ:IMUX) Advancing Its MS Drug Program? - Kalkine Media
Stifel reiterates Immunic stock rating on MS drug potential - Investing.com
Stifel reiterates Immunic stock rating on MS drug potential By Investing.com - Investing.com Canada
IMUX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $22 - GuruFocus
Immunic, Inc. R&D Day Transcript - GuruFocus
IMUX: Pivotal Phase 3 data for vidofludimus calcium in relapsing MS expected by end of 2026 - TradingView
Immunic (NASDAQ: IMUX) plans Sept. 9 relapsing MS R&D webinar - stocktitan.net
Immunic hosts RMS R&D Day webinar, presents vidofludimus calcium program and forward-looking plans - TradingView
Immunic Inc (NASDAQ: IMUX) Share Price, IMUX Stock News, IMUX Share Price & Updates - Kalkine
Immunic lines up three July investor events in Boston and SF - stocktitan.net
Small cap wrap: Immunic, Midnight Sun Mining, Purepoint Uranium... - proactiveinvestors.com.au
Immunic to host virtual R&D day on relapsing MS ahead of Phase 3 trial results - Pluang
Immunic to host virtual relapsing MS R&D Day on September 9 - Yahoo Finance
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 - PR Newswire
EQS-News: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026boerse.de - boerse.de
Immunic names Chitrang Davé chief data and digital officer - thepharmaletter.com
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer - Investing News Network
Immunic appoints Chitrang Davé as chief data and digital officer - Yahoo Finance
Roth Capital Partners Adjusts Price Target on Immunic to $29 From $19, Maintains Buy Rating - Yahoo Finance
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating (NASDAQ:IMUX) - Seeking Alpha
Long term debt to total assets ratio of Immunic, Inc. – HAM:10V - TradingView
Discontinued operations of Immunic, Inc. – HAM:10V - TradingView
Immunic Inc (IMUX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com Australia
IMUX Initiates Coverage On Wedbush -- Rating Set to Outperform - GuruFocus
Wedbush initiates Immunic stock with Outperform rating - Investing.com
Immunic Inc (IMUX) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):